MedCentralFDA Decision on Baxdrostat Would Bring First ASI to Market

⚠️ Pending FDA Approval

FDA Priority Review is underway for baxdrostat, a first-in-class aldosterone synthase inhibitor (ASI) for uncontrolled and treatment-resistant hypertension. The Phase 3 BaxHTN trial enrolled 796 patients on two or more antihypertensive agents; approval decision is expected Q2 2026.

Clinical Considerations

• Baxdrostat 2 mg produced a placebo-adjusted SBP reduction of 9.8 mmHg at 12 weeks on top of existing antihypertensive regimens.
• 24-hour and nighttime ambulatory SBP also declined significantly, suggesting sustained control beyond office measurements.
• Confirmed hyperkalemia occurred in 1.1% of baxdrostat patients versus 0% placebo; low incidence but warrants monitoring in CKD and high-potassium-risk patients.
• Aldosterone suppression occurred without cortisol impact across all doses, distinguishing it from broader adrenal-suppressing agents.

Practice Implications

• Identify patients now with resistant hypertension on three or more agents; this population is the primary approval target.
• Monitor potassium levels at baseline and during titration if baxdrostat enters your formulary post-approval.
• Avoid repositioning existing spironolactone or eplerenone patients preemptively; wait for approved prescribing guidance and head-to-head data.
• Track Q2 2026 FDA decision; first-in-class approval will likely prompt rapid guideline integration discussion

More in Drug Discoveries & Development